Mercer Global Advisors Inc. ADV increased its stake in Twist Bioscience Co. (NASDAQ:TWST – Free Report) by 14.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,899 shares of the company’s stock after buying an additional 3,752 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Twist Bioscience were worth $1,424,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience during the second quarter worth approximately $43,000. Blue Trust Inc. increased its holdings in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in Twist Bioscience during the 2nd quarter valued at $61,000. Nisa Investment Advisors LLC lifted its holdings in shares of Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after buying an additional 546 shares during the period. Finally, CWM LLC grew its position in shares of Twist Bioscience by 27.4% during the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after buying an additional 524 shares in the last quarter.

Analysts Set New Price Targets

Several research firms recently weighed in on TWST. Guggenheim started coverage on Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price objective for the company. JPMorgan Chase & Co. boosted their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Barclays lowered their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. TD Cowen lifted their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Finally, The Goldman Sachs Group upped their target price on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $48.22.

Check Out Our Latest Report on Twist Bioscience

Insider Transactions at Twist Bioscience

In related news, CFO Adam Laponis sold 842 shares of the stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $48.91, for a total value of $41,182.22. Following the completion of the transaction, the chief financial officer now directly owns 73,602 shares of the company’s stock, valued at approximately $3,599,873.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Twist Bioscience news, CEO Emily M. Leproust sold 5,139 shares of Twist Bioscience stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $205,200.27. Following the completion of the sale, the chief executive officer now owns 499,593 shares of the company’s stock, valued at approximately $19,948,748.49. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 842 shares of the stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $48.91, for a total value of $41,182.22. Following the completion of the transaction, the chief financial officer now directly owns 73,602 shares in the company, valued at $3,599,873.82. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,386 shares of company stock worth $770,915. Insiders own 3.92% of the company’s stock.

Twist Bioscience Trading Up 2.6 %

NASDAQ TWST opened at $46.46 on Wednesday. The firm’s fifty day simple moving average is $46.80 and its two-hundred day simple moving average is $43.20. The firm has a market capitalization of $2.71 billion, a P/E ratio of -13.83 and a beta of 1.76. Twist Bioscience Co. has a 12-month low of $14.42 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business had revenue of $81.50 million for the quarter, compared to analysts’ expectations of $77.40 million. During the same quarter last year, the firm earned ($1.01) earnings per share. The firm’s quarterly revenue was up 27.7% compared to the same quarter last year. As a group, sell-side analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Twist Bioscience Profile

(Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Further Reading

• Five stocks we like better than Twist Bioscience
• What Investors Must Know About Over-the-Counter (OTC) Stocks
• Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
• Dividend Payout Ratio Calculator
• Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
• How to Start Investing in Real Estate
• Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWST – Free Report).

Receive News & Ratings for Twist Bioscience Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Twist Bioscience and related companies with MarketBeat.com’s FREE daily email newsletter.